Broncus Holding Corporation (HKG:2216)

Market Cap	1.20B
Revenue (ttm)	47.72M
Net Income (ttm)	-118.94M
Shares Out	526.58M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	486,500
Average Volume	556,604
Open	2.320
Previous Close	2.300
Day's Range	2.270 - 2.320
52-Week Range	0.580 - 3.720
Beta	1.28
RSI	40.16
Earnings Date	Mar 26, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 200
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2216

Financial Performance

In 2024, Broncus Holding's revenue was $8.13 million, a decrease of -20.71% compared to the previous year's $10.26 million. Losses were -$15.30 million, -45.52% less than in 2023.

Financial numbers in USD